Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11697530 | 0.78 | DTYMK (0.60) | DTYMKCASP6TSHRLMNAHCAR3 | |
| SCHEMBL30775472 | 0.76 | DTYMK (0.58) | DTYMKCASP6TSHRLMNAHCAR3 | |
| SCHEMBL11317819 | 0.74 | DTYMK (0.56) | DTYMKCASP6TSHRLMNAHCAR3 | |
| SCHEMBL11241523 | 0.74 | DTYMK (0.56) | DTYMKCASP6TSHRLMNAHCAR3 | |
| SCHEMBL1314264 | 0.73 | ALDH1A1 (0.36) | TSHRLMNAPOLBCA1CA2 | |
| SCHEMBL772640 | 0.73 | CASP6 (0.57) | DTYMKCASP6TSHRLMNAHCAR3 | |
| SCHEMBL405684 | 0.73 | DTYMK (0.51) | DTYMKCASP6TSHRLMNACA1 | |
| SCHEMBL263830 | 0.72 | CASP6 (0.72) | DTYMKCASP6TSHRLMNAAPEX1 | |
| SCHEMBL13948939 | 0.72 | DTYMK (0.50) | DTYMKCASP6TSHRLMNACA1 | |
| SCHEMBL1851121 | 0.72 | CASP6 (0.72) | DTYMKCASP6TSHRLMNAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | Sutter West Bay Hospitals, dba California Pacific Medical Center and Catholic Healthcare West | 2009-12-03 | — | — | US | claimed |
| EP-1643987-A4 | PODOPHYLLOTOXIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2008-07-09 | — | — | EP | claimed |
| US-20080113941-A1 | Podophyllotoxin Derivatives | CALIFORNIA PACIFIC MEDICAL CENTER | 2008-05-15 | — | — | US | claimed |
| EP-1643987-A2 | PODOPHYLLOTOXIN DERIVATIVES | California Pacific Medical Center (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005014536-A2 | PODOPHYLLOTOXIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-02-17 | — | — | WO | claimed |
| US-20050004169-A1 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2005-01-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113941-A1 | Podophyllotoxin Derivatives | APEH, DAGLA, DPY30 | DTYMK 1298/4885CASP6 163/4885TSHR 3451/4885 |
| US-20050004169-A1 | Podophyllotoxin derivatives | APEH, DAGLA, DPY30 | DTYMK 1298/4885CASP6 163/4885TSHR 3451/4885 |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | APEH, DAGLA, DPY30 | DTYMK 1298/4885CASP6 163/4885TSHR 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.